Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (13,362)	$ (38,740)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Depreciation and amortization	6,317	6,015
Impairment loss on intangible assets and goodwill	0	2,021
Gain on extinguishment of debt	(4,891)	0
Loss on divestiture of business	5,244	0
Gain on settlement of contingent consideration	(14,930)	0
Change in fair value of private warrant liability	425	(345)
Change in fair value of contingent consideration	1,051	(154)
Change in fair value of derivatives	(1,483)	0
Stock-based compensation	5,368	6,894
Non-cash interest expense	10,434	1,534
Other	(799)	508
Change in operating assets and liabilities, net of acquisitions and divestitures
Accounts receivable	(439)	2,619
Reinsurance balance due	8,174	6,286
Deferred policy acquisition costs	6,752	(8,994)
Accounts payable	(3,511)	(69)
Accrued expenses and other current liabilities	1,829	1,390
Losses and loss adjustment expense reserves	17,057	14,895
Other insurance liabilities, current	9,158	16,712
Deferred revenue	(33,017)	(24,100)
Refundable customer deposits	(2,034)	(4,607)
Other assets and liabilities, net	11,122	(3,896)
Net cash provided by (used in) operating activities	8,465	(22,031)
Cash flows from investing activities:
Purchases of property and equipment	(41)	(356)
Capitalized internal use software development costs	(2,315)	(2,427)
Purchases, maturities, sales of short-term and long-term investments	4,705	(390)
Proceeds from sale of business	10,348	0
Acquisitions, net of cash acquired	0	(1,974)
Net cash provided by (used in) investing activities	12,697	(5,147)
Cash flows from financing activities:
Proceeds from advance funding	0	313
Repayments of advance funding	0	(1,281)
Repayments of principal	(3,150)	(499)
Repurchase of stock	0	(5,608)
Other	649	(199)
Net cash used in financing activities	(2,501)	(7,274)
Net change in cash and cash equivalents & restricted cash and cash equivalents	18,661	(34,452)
Cash and cash equivalents & restricted cash and cash equivalents, beginning of period	297,232	228,605
Cash and cash equivalents & restricted cash and cash equivalents, end of period	315,893	194,153
Supplemental schedule of non-cash investing and financing activities
Non-cash reduction of convertible notes	5,000	0
Non-cash reduction in advanced funding arrangement obligations	94	0
Supplemental disclosures
Cash paid for interest	969	1,796
Income tax refunds received (paid)	$ (174)	$ 2,380